张家港广大特材股份有限公司 基于对公司未来持续发展的信心和对公司长期价值的合理判断，为完善公 司长效激励机制，充分调动公司员工的积极性，提高公司员工的凝聚力，维护 全体股东利益，增强投资者对公司的投资信心，促进公司长期稳健发展，有效 地将股东利益、公司利益和员工利益紧密结合在一起，使各方合力推进公司长 远、稳定、持续的发展，独立董事一致同意公司自董事会审议通过本回购股份 方案之日起不超过 12 个月，使用中国工商银行股份有限公司张家港分行提供的 专项贷款及公司自筹资金不低于人民币 20,000 万元（含），不超过 40,000 万元 （含）通过集中竞价交易方式回购公司发行的人民币普通股（A 股）股票，回 购价格不超过人民币 39.52 元/股（含），用于员工持股计划及/或股权激励，或 用于转换上市公司发行的可转换为股票的公司债券。 经与会独立董事表决，2 票赞成、0 票反对、0 票弃权，一致通过该议案并 同意提交董事会审议。 （以下无正文） 独立董事专门会议 张家港广大特材股份有限公司独立董事专门会议 2025 年第二次会议于 席独立董事 2 人。 本次会议的召集和召开程序符合《上市公司独立董事管理办法》《张 ...

证券代码：003017 股票简称：大洋生物 公告编号：2025-057 一、公示情况说明 公司于 2025 年 6 月 7 日在巨潮资讯网（http://www.cninfo.com.cn）披露 《2025 年股权激励计划授予激励对象名单》，并于同日在公司内部对 2025 年股 权激励计划激励对象的姓名和职位予以公示，公示期自 2025 年 6 月 7 日起至 2025 年 6 月 16 日止。公示期间可向董事会秘书反馈意见，由董事会秘书报董事会薪 酬与考核委员会审核。截至 2025 年 6 月 16 日公示期满，公司董事会秘书及董事 会薪酬与考核委员会未收到任何个人或组织针对激励对象提出的异议。 二、核查方式说明 公司董事会薪酬与考核委员会核查了激励对象的姓名、身份证件、激励对象 在公司担任的职务、激励对象与公司签订的劳动合同等。 三、薪酬与考核委员会审核意见 公司第六届董事会薪酬与考核委员会第二次会议对 2025 年股权激励计划授 予对象名单进行了审核，形成审核意见如下： 浙江大洋生物科技集团股份有限公司 董事会薪酬与考核委员会对 2025 年股权激励计划激励对象名单 的审核意见及公示情况说明 本公司及董 ...

Core Points - The company held its 2024 Annual General Meeting to discuss various proposals including the board report, financial statements, and profit distribution plan [1][4][14] - The company reported a total revenue of RMB 585 million for 2024, a decrease of 7.02% year-on-year, with total assets amounting to RMB 21.989 billion and net assets of RMB 8.053 billion [8][9] - The company processed 14.3824 million tons of municipal waste in 2024, representing a year-on-year increase of 6.96%, and generated 42.609 million MWh of electricity, up 9.42% [9][10] - The company plans to distribute a cash dividend of approximately RMB 279 million, which accounts for 47.64% of the net profit attributable to shareholders for 2024 [14][15] - The company aims to continue its digital transformation and technological innovation to enhance operational efficiency and management levels [10][11] Meeting Procedures - The meeting was scheduled for June 25, 2025, at 10:00 AM, and was presided over by the acting chairman, Cheng Suning [2][4] - Attendees included shareholders, board members, supervisors, senior management, and legal representatives [2][4] - Voting was conducted through a combination of on-site and online methods, with each share carrying one vote [2][4] Financial Performance - The company achieved a net profit of RMB 585 million for 2024, with retained earnings of RMB 1.512 billion as of December 31, 2024 [14][15] - The financial budget for 2025 includes management expenses capped at RMB 306.63 million [16] Board and Supervisory Reports - The board of directors held 12 meetings in 2024 and convened 4 shareholder meetings, adhering to governance standards [11][12] - The supervisory board conducted 8 meetings, ensuring compliance with legal and regulatory requirements [12][13] Compensation Plans - The company proposed that the remuneration for directors and supervisors in 2025 remain consistent with 2024 levels, with independent directors receiving annual fees of RMB 80,000 and HKD 120,000 for those residing in Hong Kong [17][19]

Core Viewpoint - The independent financial advisor report by Shenwan Hongyuan Securities evaluates the stock option incentive plan of Shenzhen New Star Light Alloy Materials Co., Ltd. for 2025, confirming its feasibility and alignment with relevant regulations [1][2][3]. Group 1: Stock Option Incentive Plan Overview - The stock option incentive plan aims to grant stock options to a total of 6 individuals, representing 0.95% of the company's total share capital [4][6]. - The plan includes a waiting period of 12 to 24 months before the options can be exercised, with a maximum validity of 36 months [8][10]. - The exercise price for the stock options is set at 13.33 RMB per share, which is based on the average trading price of the company's shares prior to the announcement [7][20]. Group 2: Performance Assessment Criteria - The performance assessment for the incentive plan is divided into company-level and individual-level evaluations, with the company-level targets based on revenue growth compared to the previous year [19][21]. - The revenue growth targets for the first assessment year (2025) are set at a minimum of 18% compared to 2024, while for the second year (2026), the target is 48% [15][19]. - Individual performance will be assessed annually, determining the proportion of options that can be exercised based on performance ratings [19][21]. Group 3: Compliance and Feasibility - The report confirms that the company meets the conditions for implementing the stock option incentive plan as outlined in the relevant regulations, with no disqualifying circumstances present [21][22]. - The plan has been structured to ensure that it does not harm the interests of the company or its shareholders, with provisions in place to terminate the plan if certain negative conditions arise [21][22]. - The independent financial advisor believes that the implementation of this incentive plan will positively impact the company's operational sustainability and shareholder equity in the long term [21].

证券代码：603568 证券简称：伟明环保 公告编号：临 2025-042 转债代码：113652 转债简称：伟 22 转债 转债代码：113683 转债简称：伟 24 转债 浙江伟明环保股份有限公司 关于股权激励限制性股票回购注销实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 回购注销原因：浙江伟明环保股份有限公司（以下简称"公司"）2023 年限制性股票激励计划中，1 名激励对象因个人原因已离职，不再符合激励计划 中有关激励对象的规定，公司决定取消其激励对象资格并回购注销其已获授但尚 未解除限售的全部限制性股票。 ? 本次注销股份的有关情况 回购股份数量（股） 注销股份数量（股） 注销日期 一、本次限制性股票回购注销的决策与信息披露 （一） 2025 年 4 月 25 日，公司召开第七届董事会第十四次会议和第七届监 事会第九次会议，审议通过了《关于回购注销部分限制性股票及调整回购价格的 议案》，同意回购注销 1 名激励对象已获授但尚未解除限售的限制性股票共计 会审议通过。国浩律师出具了《关于浙 ...

证券代码：688636 证券简称：智明达 公告编号：2025-026 成都智明达电子股份有限公司 关于调整 2023 年限制性股票激励计划第二类限制性股票 授予价格和数量的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 成都智明达电子股份有限公司（以下简称"公司"）于 2025 年 6 月 16 日召 开了第三届董事会第二十五次会议，审议通过了《关于调整 2023 年限制性股票 激励计划第二类限制性股票授予价格及数量的议案》等议案，同意公司按照《上 市公司股权激励管理办法》 （以下简称《管理办法》）、 《成都智明达电子股份有限 《关于提请股东大会授权董事会办理 2023 年限制性股票激励计划相关事宜 的议案》等议案，公司独立董事就本激励计划发表了独立意见，律师、独立财务 顾问出具了相应报告。公司于 2023 年 5 月 17 日披露了《2023 年限制性股票激 励计划（草案）》及其摘要。 （二）2023 年 5 月 17 日至 2023 年 5 月 26 日，公司对本激励计划激励对象 的姓名与职务在公司内部进行了公示 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 三祥新材股份有限公司（以下简称"三祥新材"）近日发布股权激励限制性股票回购注销实施公告，因 2022年股票期权与限制性股票激励计划相关业绩未达考核目标，公司将回购注销642,390股限制性股 票。 业绩未达标触发回购注销 根据公告，三祥新材2022年股票期权与限制性股票激励计划中，首次授予第三个解除限售期和预留授予 第二个解除限售期公司层面业绩需以2019 - 2021年三年净利润算术平均值为基数，2024年净利润增长率 不低于150%。但公司2024年年报显示，该业绩考核目标未达成。因此，首次授予的70名激励对象计划 解除限售的532,140股限制性股票，以及预留授予的10名激励对象计划解除限售的110,250股限制性股 票，均不得解除限售，公司将对这642,390股限制性股票进行回购注销处理。 回购注销具体安排 2025年4月23日，三祥新材召开第五届董事会第八次会议和第五届监事会第八次会议，审议通过相关议 案。4月25日，公司发布减资通知债权人的公告。公司已在中登公司开设回购专用证券账户，并递交回 购注销申请，预计于2025年6月19日完成回购注销，后续 ...

股票代码：000999 股票简称：华润三九 编号：2025—050 华润三九医药股份有限公司 关于 2021 年限制性股票激励计划第三个解锁期解锁条件未成就 暨回购注销首次授予、预留授予部分限制性股票的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 重要内容提示： ●本次回购注销的限制性股票数量：474.7942 万股，其中首次授予的限制性股票数量 为 408.7113 万股，预留授予的限制性股票数量为 66.0829 万股（具体股数以中国证券登记 结算有限责任公司深圳分公司提供的为准），涉及人数 363 人。 ●本次回购限制性股票的价格：408.7113 万股（具体股数以中国证券登记结算有限责 任公司深圳分公司提供的为准）首次授予限制性股票以调整后回购价格（5.7817625 元/股） 进行回购注销；66.0829 万股（具体股数以中国证券登记结算有限责任公司深圳分公司提供 的为准）预留授予限制性股票以调整后回购价格（11.3988165 元/股）进行回购注销；回购 资金均为公司自有资金。 ●本次回购注销部分限制性股票尚需提交公司股东会进行审议。 华润 ...

Investment Rating - The report assigns a "Buy" rating to the company, indicating a potential upside of 15% to 35% from the current price [2][8]. Core Insights - The company has launched a new stock incentive plan aimed at enhancing growth, targeting a revenue increase of 20%, 44%, and 72.8% for the years 2025 to 2027, respectively, compared to 2024 [8][11]. - The domestic medical equipment market is showing significant recovery, with a 100.36% year-on-year growth in the medical imaging equipment market and a 72.41% growth in the radiation therapy equipment market from January to May 2025 [11]. - The company is expected to achieve net profits of RMB 16.4 billion, RMB 20.0 billion, and RMB 24.2 billion for the years 2025 to 2027, representing year-on-year growth rates of 30.3%, 22.0%, and 20.8%, respectively [11]. Company Overview - The company operates primarily in the medical and biological industry, with a market capitalization of RMB 768.32 billion and a current share price of RMB 129.50 [1]. - The product mix includes 87.8% from medical imaging diagnostic equipment and radiation therapy equipment, 9.5% from maintenance services, and 1.1% from software business [3]. Financial Projections - The company is projected to have a net profit of RMB 1.644 billion in 2025, with an earnings per share (EPS) of RMB 1.99, and a price-to-earnings (P/E) ratio of 64.94 [10][11]. - Revenue is expected to grow from RMB 12.984 billion in 2025 to RMB 18.260 billion by 2027, with corresponding operating profits increasing from RMB 1.733 billion to RMB 2.604 billion [15].

Core Viewpoint - The company plans to repurchase and cancel a total of 230,800 restricted stocks due to the termination of labor relations with 12 original incentive targets who are no longer eligible for the incentive program [2][4][6]. Summary by Sections Repurchase and Cancellation Reasons - The repurchase and cancellation of restricted stocks are based on the "Management Measures for Equity Incentives of Listed Companies" and the relevant provisions of the company's second and third phase restricted stock incentive plans [2][4]. Details of the Repurchase - The total number of restricted stocks to be repurchased is 230,800, with a total repurchase price of RMB 2,518,773.81 [2][4]. - The decision was approved in the 21st meeting of the fifth board of directors and the 15th meeting of the fifth supervisory board on April 25, 2025 [2][4]. Notification and Legal Compliance - The company has fulfilled the creditor notification procedures as required by law, and no claims have been made by creditors during the 45-day public notice period [3][4]. - The company has opened a dedicated securities account for the repurchase and has applied for the transfer procedures for the repurchased stocks [7]. Changes in Share Structure - After the repurchase and cancellation, the remaining restricted stocks will total 9,372,920 [6][7]. Legal Opinions - The legal opinion from Beijing Jiayuan Law Firm confirms that the repurchase and cancellation have received necessary approvals and comply with relevant laws and regulations [8].